This segment focuses on the discovery, development, and commercialization of novel therapies for neurological disorders. Key research and development activities include preclinical studies and clinical trials for drug candidates targeting ion channels, particularly Kv7 potassium channels and Nav1.6 sodium channels. These efforts aim to address unmet medical needs in epilepsy, developmental and epileptic encephalopathies, and other neurological conditions. The segment's market positioning is centered on precision medicine and personalized approaches to treating neurological diseases, with a focus on improving patient outcomes and quality of life. Future opportunities include expanding the pipeline with new drug candidates and exploring additional therapeutic applications for existing compounds. Collaborations with partners like Neurocrine Biosciences are crucial for advancing the development and commercialization of these therapies.